Evidence map›Paper›PMID 31783691›Full record

ArticleCancers2019

Enhanced Hsa-miR-181d/p-STAT3 and Hsa-miR-181d/p-STAT5A Ratios Mediate the Anticancer Effect of Garcinol in

Heng-Wei Liu, Peter Mingjui Lee, Oluwaseun Adebayo Bamodu, Yu-Kai Su, Iat-Hang Fong, Chi-Tai Yeh, Ming-Hsien Chien, I-Hung Kan, Chien-Min Lin

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Frontiers in oncology · 2021
    Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Identification and Validation ofOncoTargets and therapy · 2020
    Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Heng-Wei LiuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
Peter Mingjui LeeDepartment of Clinical Oncology, College of Medicine, California North State University, Elk Grove, CA 95757, USA.
Oluwaseun Adebayo BamoduTaipei Neuroscience Institute, Taipei Medical University, Taipei 11031, Taiwan.ORCID 0000-0001-8229-0408
Yu-Kai SuGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
Iat-Hang FongDivision of Neurosurgery, Department of Surgery, Taipei Medical University-Shuang Ho Hospital, New Taipei City 23561, Taiwan.
Chi-Tai YehGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.ORCID 0000-0001-5189-9755
Ming-Hsien ChienGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
I-Hung KanGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.
Chien-Min LinGraduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei City 11031, Taiwan.ORCID 0000-0001-5404-0145
Taipei Medical University-Shuang Ho Hospital · TWCalifornia Northstate University · USTaipei Medical University · TWYuanpei University · TW

Funding

Ministry of Science and Technology, Taiwan MOST 107-2314-B-038 -056 -MY3
6 · The paper itself

Abstract

backgroundGlioblastoma (GBM), a malignant grade IV tumor, is the most malignant brain tumor due to its hyper-proliferative and apoptosis-evading characteristics. The signal transducer and activators of transcription (STAT) family genes, including MATERIAL AND

methodsThe present study investigated the anti-GBM effects of garcinol, focusing on the

resultsOur bioinformatics analysis of The Cancer Genome Atlas (TCGA)-GBM cohort (

conclusionsWe present evidence of anti-GBM efficacy of garcinol mediated by enhancing the hsa-miR-181d/STAT3 and hsa-miR-181d/5A ratios in GBM cells. Our findings suggest a potential new therapeutic agent for combating aggressive GBM.

Indexed as

GBMglioblastomagliomahsa-miR-181dmicroRNASTAT3STAT5A

Identifiers

PMID31783691
PMCPMC6966688
OpenAlexW2990481690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.